# Sex differences in growth response to GH treatment:

## more prepubertal and less pubertal gain in girls diagnosed with IGHD, ISS, SGA.

Elena Lundberg<sup>1\*</sup>, Berit Kriström<sup>1\*</sup>, Aldina Pivodic<sup>2</sup> and Kerstin Albertsson-Wikland<sup>2\*</sup>

<sup>1</sup>Inst of Clinical Sciences, Pediatrics, Umeå University, Umea, <sup>2</sup>Department of Clinical Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Sweden



#### Aim

To describe and identify factors explaining growth response to GH-treatment, separately in girls and boys from GH-start before and during puberty to adult height (AH).

### Background

Due to fewer girls than boys being GH-treated, after 50yrs the knowledge about sex-differences in both GH-response and GH-responsiveness before and during puberty remains limited.

#### **Material**

Children (3-18 yrs) diagnosed with IGHD, ISS, SGA from our GH-SAFETY-database, including all rhGH-treated children during 1986-2009 in Sweden, from National-GH-Registry and from rhGH-clinical-trials were included<sup>1</sup>.

Inclusion criteria for the present study was complete data for the following variables: gestational age(GA) ≥32 weeks; birth size >-4 SDS<sup>2</sup>; longitudinal heights and weights from birth to AH, age and height/weight at pubertal stage B2/testis 4ml; mid-parental height (MPH); GH<sub>max</sub>AITT/12-24h-GHprofile; rhGHstart at age ≥3yrs; available rhGHdose (µg/kg/day); resulting in 604 patients, 420 boys and 184 girls.


#### **Methods**

Growth response outcomes were: change vs population<sup>3</sup> ( $\Delta$ height<sub>SDS</sub>), and vs parents (DiffH-MPH<sub>SDS</sub>) for the GHtreatment periods: prepubertal1yr, 2yrs, prepubertal period (GHstart to last prepubertal visit using prepubertal reference), pubertal (last prepubertal visit to AH using reference at age 18yrs for AH<sub>SDS</sub>), and total height gain<sub>SDS</sub> (GHstart to AH). Fisher's non-parametric permutation test and linear regression was applied. Value for significance was p<0.05.

#### Conclusion

- Prepubertal period: girls responded more than the boys, being more GH-responsive being younger and shorter vs parents and population at GHstart; in addition, they received higher GH-doses
- Pubertal period: the group of girls lost 20% of the prepubertal attained height<sub>sps</sub> during puberty, whereas maintained in the group of boys on similar GH-doses. However, 50% of the boys and 75% of the girls had no pubertal gain (see ellipse in the figure)
- Adult height<sub>SDS</sub> was for girls and boys -1.7 respectively -1.25; while mean total gain in height<sub>SDS</sub> for girls vs boys was 1.3 vs 1.5

#### Results Height gain (SDS) during indicated period (median, range)





	Boys=420 Mean(SD)	Girls=184 Mean(SD)	p-value
Birth/infancy			
BirthLengthsds	-1.60(1.14)	-1.70(1.15)	0.31
BirthWeightsds	-1.06(1.09)	-0.98(1.18)	0.42
Infancy∆Height <sub>SDS</sub> 0-2yrs	-0.51(1.11)	-0.82(1.09)	0.0019
DiffH-MPH <sub>SDS</sub> 2yrs	-1.12(1.03)	-1.38(1.02)	0.0042
Pretreatment/at GHstart			
ΔHeight <sub>SDS</sub> Pretreatment	-0.03(0.23)	0.02(0.23)	0.015
GH <sub>max</sub> AITT/GHprofile	16.1(19.1)	15.7(14.4)	0.81
Age(yr)GHstart	8.65(2.12)	7.86(2.17)	<.0001
HeightspsGHstart	-2.72(0.52)	-2.97(0.58)	<.0001
Outcome on rhGH treatment			
ΔHeight <sub>SDS</sub> 1 <sup>yr</sup>	0.71(0.26)	0.80(0.29)	0.0011
GHdose(µg/kg/day)1 <sup>yr</sup>	35.9(9.2)	39.1(12.2)	0.0029
∆Height <sub>SDS</sub> Prepubertal	1.48(0.65)	1.63(1.12)	0.012
GHdose(µg/kg/day)Prepubertal	35.8(8.0)	39.0(11.6)	0.0002
∆Height <sub>SDS</sub> Pubertal	-0.005(0.69)	-0.36(0.68)	<.0001
GHdose(µg/kg/day)Pubertal	30.1(10.0)	30.3(9.8)	0.80
∆Height <sub>sDS</sub> GHstart-AH	1.47(0.80)	1.27(0.80)	0.0037
GHdose(µg/kg/day)GHstart-AH	32.5(7.9)	33.9(8.8)	0.051
At adult height			
Height,cm	172.2(6.0)	157.2(5.4)	<.0001
Height <sub>SDS</sub>	-1.25(0.92)	-1.70(0.89)	<.0001

-0.26(0.93)

-0.57(0.83)

0.0002

#### References.

<sup>1</sup>Albertsson-Wikland.et al.JCEM2016;101(5):2149-59. <sup>2</sup>Niklasson&Albertsson-Wikland.et al.ActaPead.2002;91(7):739-54. <sup>4</sup>Kriström.et al.BMC.2009;12(9)1:1.

DiffH-MPH<sub>SDS</sub>

**Diclosure**: EL, BK, AP, KAW have nothing to declare. elena.lundberg@umu.se

